Suppr超能文献

溶栓相关症状性脑出血的管理

Management of thrombolysis-associated symptomatic intracerebral hemorrhage.

作者信息

Goldstein Joshua N, Marrero Marisela, Masrur Shihab, Pervez Muhammad, Barrocas Alex M, Abdullah Abdul, Oleinik Alexandra, Rosand Jonathan, Smith Eric E, Dzik Walter H, Schwamm Lee H

机构信息

Department of Emergency Medicine, Massachusetts General Hospital, Zero Emerson Place, Ste 3B, Boston, MA 02114, USA.

出版信息

Arch Neurol. 2010 Aug;67(8):965-9. doi: 10.1001/archneurol.2010.175.

Abstract

BACKGROUND

Symptomatic intracerebral hemorrhage (sICH) is the most devastating complication of thrombolytic therapy for acute stroke. It is not clear whether patients with sICH continue to bleed after diagnosis, nor has the most appropriate treatment been determined.

METHODS

We performed a retrospective analysis of our prospectively collected Get With the Guidelines-Stroke database between April 1, 2003, and December 31, 2007. Radiologic images and all procoagulant agents used were reviewed. Multivariable logistic regression was performed to identify factors associated with in-hospital mortality.

RESULTS

Of 2362 patients with acute ischemic stroke during the study period, sICH occurred in 19 of the 311 patients (6.1%) who received intravenous tissue plasminogen activator and 2 of the 72 (2.8%) who received intra-arterial thrombolysis. In-hospital mortality was significantly higher in patients with sICH than in those without (15 of 20 [75.0]% vs 56 of 332 [16.9%], P < .001). Eleven of 20 patients (55.0%) received therapy for coagulopathy: 7 received fresh frozen plasma; 5, cryoprecipitate; 4, phytonadione (vitamin K(1)); 3, platelets; and 1, aminocaproic acid. Independent predictors of in-hospital mortality included sICH (odds ratio, 32.6; 95% confidence interval, 8.8-120.2), increasing National Institutes of Health Stroke Scale score (1.2; 1.1-1.2), older age (1.3; 1.0-1.7), and intra-arterial thrombolysis (2.9; 1.4-6.0). Treatment for coagulopathy was not associated with outcome. Continued bleeding (>33% increase in intracerebral hemorrhage volume) occurred in 4 of 10 patients with follow-up scans available (40.0%).

CONCLUSIONS

In many patients with sICH after thrombolysis, coagulopathy goes untreated. Our finding of continued bleeding after diagnosis in 40.0% of patients suggests a powerful opportunity for intervention. A multicenter registry to analyze management of thrombolysis-associated intracerebral hemorrhage and outcomes is warranted.

摘要

背景

症状性脑出血(sICH)是急性卒中溶栓治疗最严重的并发症。目前尚不清楚sICH患者在确诊后是否继续出血,也未确定最恰当的治疗方法。

方法

我们对2003年4月1日至2007年12月31日期间前瞻性收集的“遵循卒中指南”数据库进行了回顾性分析。对放射影像和使用的所有促凝剂进行了审查。采用多变量逻辑回归分析确定与院内死亡相关的因素。

结果

在研究期间的2362例急性缺血性卒中患者中,311例接受静脉注射组织型纤溶酶原激活剂的患者中有19例(6.1%)发生sICH,72例接受动脉内溶栓的患者中有2例(2.8%)发生sICH。sICH患者的院内死亡率显著高于无sICH的患者(20例中有15例[75.0%] vs 332例中有56例[16.9%],P <.001)。20例患者中有11例(55.0%)接受了凝血病治疗:7例接受新鲜冰冻血浆;5例接受冷沉淀;4例接受维生素K1;3例接受血小板;1例接受氨基己酸。院内死亡的独立预测因素包括sICH(比值比,32.6;95%置信区间,8.8 - 120.2)、美国国立卫生研究院卒中量表评分增加(1.2;1.1 - 1.2)、年龄较大(1.3;1.0 - 1.7)和动脉内溶栓(2.9;1.4 - 6.0)。凝血病治疗与预后无关。在10例有随访扫描结果的患者中,4例(40.0%)出现持续出血(脑出血体积增加>33%)。

结论

在许多溶栓后发生sICH的患者中,凝血病未得到治疗。我们发现40.0%的患者在诊断后持续出血,这提示了一个有力的干预机会。有必要建立一个多中心登记系统来分析溶栓相关脑出血的管理及预后。

相似文献

1
Management of thrombolysis-associated symptomatic intracerebral hemorrhage.
Arch Neurol. 2010 Aug;67(8):965-9. doi: 10.1001/archneurol.2010.175.
2
Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
J Stroke Cerebrovasc Dis. 2019 Nov;28(11):104360. doi: 10.1016/j.jstrokecerebrovasdis.2019.104360. Epub 2019 Sep 14.
4
Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.
J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1235-43. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.026. Epub 2015 Apr 16.
5
Treatment and Outcome of Thrombolysis-Related Hemorrhage: A Multicenter Retrospective Study.
JAMA Neurol. 2015 Dec;72(12):1451-7. doi: 10.1001/jamaneurol.2015.2371.
8
Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Int J Stroke. 2016 Oct;11(7):783-90. doi: 10.1177/1747493016654289. Epub 2016 Jun 16.
9
10
Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis.
Neurocrit Care. 2015 Apr;22(2):229-33. doi: 10.1007/s12028-014-0060-2.

引用本文的文献

1
Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality.
Neurocrit Care. 2024 Dec;41(3):788-797. doi: 10.1007/s12028-024-01996-2. Epub 2024 May 15.
2
Treatment and Outcomes of Thrombolysis Related Hemorrhagic Transformation: A Multi-Center Study in China.
Front Aging Neurosci. 2022 Apr 7;14:847648. doi: 10.3389/fnagi.2022.847648. eCollection 2022.
3
Glutamate Scavenging as a Neuroreparative Strategy in Ischemic Stroke.
Front Pharmacol. 2022 Mar 23;13:866738. doi: 10.3389/fphar.2022.866738. eCollection 2022.
4
Radiomics-based prediction of hemorrhage expansion among patients with thrombolysis/thrombectomy related-hemorrhagic transformation using machine learning.
Ther Adv Neurol Disord. 2021 Nov 24;14:17562864211060029. doi: 10.1177/17562864211060029. eCollection 2021.
5
Hemorrhagic Transformation After Ischemic Stroke: Mechanisms and Management.
Front Neurol. 2021 Nov 30;12:703258. doi: 10.3389/fneur.2021.703258. eCollection 2021.
6
Adverse consequences of immediate thrombolysis-related complications: a multi-centre registry-based cohort study of acute stroke.
J Thromb Thrombolysis. 2022 Jan;53(1):218-227. doi: 10.1007/s11239-021-02523-2. Epub 2021 Jul 13.
9
Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase.
J Atheroscler Thromb. 2020 Nov 1;27(11):1176-1182. doi: 10.5551/jat.49783. Epub 2020 Feb 28.
10
Early Acute Ischemic Stroke Management for Pharmacists.
Hosp Pharm. 2020 Feb;55(1):12-25. doi: 10.1177/0018578718791504. Epub 2018 Aug 7.

本文引用的文献

2
Off-hour admission and in-hospital stroke case fatality in the get with the guidelines-stroke program.
Stroke. 2009 Feb;40(2):569-76. doi: 10.1161/STROKEAHA.108.519355. Epub 2008 Nov 6.
3
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
4
Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
Lancet. 2008 Oct 11;372(9646):1303-9. doi: 10.1016/S0140-6736(08)61339-2. Epub 2008 Sep 12.
5
Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.
N Engl J Med. 2008 May 15;358(20):2127-37. doi: 10.1056/NEJMoa0707534.
6
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.
Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.
7
Hemostatic therapy for the treatment of intracranial hemorrhage.
Pharmacotherapy. 2008 Apr;28(4):485-95. doi: 10.1592/phco.28.4.485.
8
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
Stroke. 2008 Mar;39(3):924-8. doi: 10.1161/STROKEAHA.107.490375. Epub 2008 Jan 31.
9
Warfarin reversal in anticoagulant-associated intracerebral hemorrhage.
Neurocrit Care. 2008;9(2):277-83. doi: 10.1007/s12028-008-9049-z.
10
Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign.
Stroke. 2008 Feb;39(2):379-83. doi: 10.1161/STROKEAHA.107.492348. Epub 2007 Dec 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验